Email Print this page Bookmark this page

LACRISERT® Efficacy Data

The following data demonstrate the efficacy of LACRISERT® in treating Dry Eye:

8 Out of 10 Dry Eye Patients Preferred LACRISERT® to Artificial Tears1

 

 

LACRISERT® Significantly Improves the Signs of Dry Eye Better Than Artificial Tears*1

 

 

Dry Eye occurs as a result of tear film instability, which can leave the ocular surface exposed and unprotected. In a 4-week crossover study, patients who used LACRISERT® once daily experienced significant improvement of the tear film versus patients who used artificial tear drops 4 times a day, as demonstrated by rose bengal staining.*1

*All objective signs were ranked on a scale from 0 to 4, ranging from absent to mild, moderate, severe, or extreme. There was no significant difference on the measure of visual acuity between LACRISERT® and artificial tear treatments. Patients were divided into 2 treatment groups in a randomized fashion.1

 

LACRISERT® Significantly Improves Dry Eye Symptoms Better Than Artificial Tears1

 

 

In a 4-week crossover study, symptoms were significantly improved in patients administering LACRISERT® once daily versus patients administering artificial tears 4 times a day. LACRISERT® patients experienced less burning, foreign body sensation, itching, smarting, soreness, and dryness.†1

All subjective symptoms were ranked on a scale from 0 to 4, ranging from absent to mild, moderate, severe, or extreme. There was no significant difference on the measure of blurred vision, tearing, and photophobia between LACRISERT® and artificial tear treatments. Patients were divided into 2 treatment groups in a randomized fashion.1

 

Dry Eye Symptoms Improve Significantly With Long-term Treatment With LACRISERT®‡2

 

 

A 52-week study showed that patients’ symptoms were increasingly less severe with continued use of LACRISERT®. Patients saw greatest benefit by 6 to 9 weeks of use.‡2

All subjective symptoms were ranked on a scale from 0 to 4, ranging from no involvement to severe involvement.2

Indications and Usage

LACRISERT® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

LACRISERT® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT® should be carefully followed. If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery. Patients should be cautioned against rubbing the eye(s) containing LACRISERT®.

The following adverse reactions have been reported, but were in most instances, mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

References: 1. Katz, JI, Kaufman HE, Breslin C, Katz IM. Slow-release artificial tears and the treatment of keratitis sicca. Ophthalmology. 1978;85(8):787-793. 2. Werblin TP, Rheinstrom SD, Kaufman HE. The use of slow-release artificial tears in the long-term management of keratitis sicca. Ophthalmology. 1981;88(1):78-81.

 

sample request using Lacrisert video patient tip sheet
©2012 Valeant Ophthalmics, a division of Valeant Pharmaceuticals North America LLC          Bridgewater, NJ 08807